Next, we tested the PeptiCRAd platform with VALO-mD901 in a syngeneic mouse model of B16.F10.9/K1 melanoma using a more relevant, tumor-associated antigen from tyrosinase-related protein 2 (Trp2180–188). This evidence concerns the gene DCT and neoplasm.